Polyrizon Ltd. Ordinary Shares (PLRZ)

Price$11.64

Favorite Metrics

Price vs S&P 500 (26W)61.04%

Price vs S&P 500 (4W)-26.21%

Market Capitalization$20.34M

All Metrics

Book Value / Share (Quarterly)$13.05

P/TBV (Annual)0.73x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.82

Price vs S&P 500 (YTD)30.26%

EPS (TTM)$-5.64

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-5.64

EPS (Annual)$-4.90

ROI (Annual)-15.89%

Cash / Share (Quarterly)$7.75

ROA (Last FY)-15.56%

EBITD / Share (TTM)$-25.05

Cash Flow / Share (Annual)$-2.82

P/B Ratio0.97x

P/B Ratio (Quarterly)0.64x

Net Income / Employee (Annual)$-3

Net Interest Coverage (TTM)-5.44x

ROA (TTM)-17.48%

EPS Incl Extra (Annual)$-4.90

Current Ratio (Annual)29.03x

Quick Ratio (Quarterly)29.03x

3-Month Avg Trading Volume0.11M

52-Week Price Return-97.90%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$11.47

52-Week High$2235.00

EPS Excl Extra (Annual)$-4.90

26-Week Price Return69.79%

Quick Ratio (Annual)29.03x

13-Week Price Return-24.44%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)29.03x

Enterprise Value$19.036

Revenue / Employee (Annual)$0

Cash / Share (Annual)$7.75

3-Month Return Std Dev112.91%

Net Income / Employee (TTM)$-4

ROE (Last FY)-15.89%

EPS Basic Excl Extra (Annual)$-4.90

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.64

ROI (TTM)-17.84%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$11.47

Price vs S&P 500 (52W)-133.00%

Year-to-Date Return34.39%

5-Day Price Return-4.04%

EPS Normalized (Annual)$-4.90

ROA (5Y Avg)-79.38%

Month-to-Date Return-2.31%

EBITD / Share (Annual)$-13.36

EPS Basic Excl Extra (TTM)$-5.64

P/TBV (Quarterly)0.73x

P/B Ratio (Annual)0.64x

Book Value / Share (Annual)$13.05

Price vs S&P 500 (13W)-27.30%

Beta1.01x

Revenue / Share (TTM)$0.00

ROE (TTM)-17.84%

52-Week Low$2.88

About

Polyrizon Ltd is a clinical-stage biotech company developing nasal gel treatments designed to provide preventative protection against viruses including COVID-19 variants, influenza, and allergens. The company's proprietary platforms—Capture & Contain and Trap & Target—deliver broad-spectrum respiratory pathogen defense.